Ovarian cancer is the eighth most common neoplasm in women with a high mortality rate mainly due to a marked propensity for peritoneal spread directly at diagnosis, as well as tumor recurrence after radical surgical treatment. Treatments for peritoneal metastases have to be designed from a patient’s perspective and focus on meaningful measures of benefit. Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery with regional chemotherapy, has been proposed to treat advanced ovarian cancer. Preliminary results to date have shown promising results, with improved survival outcomes and tumor regression. As knowledge about the disease process increases, practice guidelines will continue to evolve. In this review, we have reported a broad overview of advanced ovarian cancer management, and an update of the current evidence. The future perspectives of the Italian Society of Surgical Oncology (SICO) are discussed conclusively.

Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes / Marrelli, D.; Ansaloni, L.; Federici, O.; Asero, S.; Carbone, L.; Marano, L.; Baiocchi, G.; Vaira, M.; Coccolini, F.; Di Giorgio, A.; Framarini, M.; Gelmini, R.; Palopoli, C.; Accarpio, F.; Fagotti, A.. - In: CANCERS. - ISSN 2072-6694. - 14:23(2022), pp. 6010-6032. [10.3390/cancers14236010]

Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes

Gelmini R.;
2022

Abstract

Ovarian cancer is the eighth most common neoplasm in women with a high mortality rate mainly due to a marked propensity for peritoneal spread directly at diagnosis, as well as tumor recurrence after radical surgical treatment. Treatments for peritoneal metastases have to be designed from a patient’s perspective and focus on meaningful measures of benefit. Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery with regional chemotherapy, has been proposed to treat advanced ovarian cancer. Preliminary results to date have shown promising results, with improved survival outcomes and tumor regression. As knowledge about the disease process increases, practice guidelines will continue to evolve. In this review, we have reported a broad overview of advanced ovarian cancer management, and an update of the current evidence. The future perspectives of the Italian Society of Surgical Oncology (SICO) are discussed conclusively.
2022
dic-2022
14
23
6010
6032
Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes / Marrelli, D.; Ansaloni, L.; Federici, O.; Asero, S.; Carbone, L.; Marano, L.; Baiocchi, G.; Vaira, M.; Coccolini, F.; Di Giorgio, A.; Framarini, M.; Gelmini, R.; Palopoli, C.; Accarpio, F.; Fagotti, A.. - In: CANCERS. - ISSN 2072-6694. - 14:23(2022), pp. 6010-6032. [10.3390/cancers14236010]
Marrelli, D.; Ansaloni, L.; Federici, O.; Asero, S.; Carbone, L.; Marano, L.; Baiocchi, G.; Vaira, M.; Coccolini, F.; Di Giorgio, A.; Framarini, M.; Gelmini, R.; Palopoli, C.; Accarpio, F.; Fagotti, A.
File in questo prodotto:
File Dimensione Formato  
cancers-2022 ovaio hipec.pdf

Open access

Descrizione: paper
Tipologia: Versione pubblicata dall'editore
Dimensione 2.84 MB
Formato Adobe PDF
2.84 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1293786
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact